Sue Yom

MD PhD

Radiation oncologist

Dr. Sue Yom is an expert in the radiation treatment and management of head, neck and lung cancers.

In her research, Yom studies chemoradiation (a combination of chemotherapy and radiation) for these cancers. She also investigates image-guided radiation therapy and ways to reduce toxic effects using focused radiation techniques, emerging biological agents and radiation protectants.

Yom earned her medical and doctoral degrees at the University of Pennsylvania. She completed a residency in radiation oncology at the MD Anderson Cancer Center.

Yom has received numerous awards recognizing her commitment to patient care and patient-oriented research.

  • Education

    University of Pennsylvania School of Medicine, 2002

  • Residencies

    University of Texas Anderson Cancer Center, Radiation Oncology, 2007

  • Board Certifications

    Radiation Oncology, American Board of Radiology

  • Academic Title

    Professor

I am a passionate advocate for my patients in helping them achieve their best outcomes, both in health and quality of life.

Conditions I specialize in

Treatments I provide

Where I see patients (4)

    My reviews

    5.0

    Overall Experience
    173 Ratings
    Explained things in a way that was easy to understand
    173 Ratings
    Did the doctor pay attention to your concerns
    173 Ratings
    Gave easy to understand instructions about taking care of health problems or concerns
    168 Ratings
    Knew the important information about your medical history
    173 Ratings
    The provider showed respect for what you had to say
    171 Ratings
    The provider spent enough time with me
    172 Ratings
    Read all reviews About our process

    Selected research

    Decorative Caduceus

    Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usua...

    Estimated using the Kaplan-Meier method for each arm. Their distributions will be compared between treatment arms with a one-sided log rank test.

    Recruiting

    Decorative Caduceus

    Nivolumab + Chemoradiation in Stage II-IVB Nasopharyngeal Carcinoma (NPC)

    The rate of completion of all adjuvant therapy by patients treated at the maximum tolerated dose (MTD) schedule will be determined and compared to a historical control rate of 52%.

    Recruiting

    Contact me

    Providers on my team

    Share